Treatment with Toca 511 and Toca FC did not improve overall survival (OS) compared with standard therapy in patients with recurrent high-grade glioma undergoing resection, missing the primary endpoint of the phase III Toca 5 trial.1
= .003). Moreover, tumor samples from patients who survived ≥52 weeks after Toca 511 delivery disproportionately displayed a survival-related mRNA expression signature, which identified a potential molecular signature with possible correlation with treatment-related survival versus it being a prognostic factor.
- Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer. Tocagen. Published September 12, 2019. https://bit.ly/2lPm19v. Accessed September 12, 2019.
- Cloughesy TF, Landolfi J, Hogan DJ, et al. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci Transl Med. 2016 Jun 1;8(341):341ra75. doi: 10.1126/scitranslmed.aad9784.
... to read the full story